Cargando…

Iron Replacement Therapy with Oral Ferric Maltol: Review of the Evidence and Expert Opinion

Iron deficiency is the most common cause of anemia globally and is frequently reported in patients with underlying inflammatory conditions, such as inflammatory bowel disease (IBD) and chronic kidney disease (CKD). Ferric maltol is a new oral iron replacement therapy designed to optimize iron absorp...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, Carsten, Allen, Stephen, Kopyt, Nelson, Pergola, Pablo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509126/
https://www.ncbi.nlm.nih.gov/pubmed/34640466
http://dx.doi.org/10.3390/jcm10194448
_version_ 1784582259650592768
author Schmidt, Carsten
Allen, Stephen
Kopyt, Nelson
Pergola, Pablo
author_facet Schmidt, Carsten
Allen, Stephen
Kopyt, Nelson
Pergola, Pablo
author_sort Schmidt, Carsten
collection PubMed
description Iron deficiency is the most common cause of anemia globally and is frequently reported in patients with underlying inflammatory conditions, such as inflammatory bowel disease (IBD) and chronic kidney disease (CKD). Ferric maltol is a new oral iron replacement therapy designed to optimize iron absorption while reducing the gastrointestinal adverse events associated with unabsorbed free iron. Ferric maltol has been studied in clinical trials involving almost 750 adults and adolescents with iron-deficiency anemia associated with IBD, CKD, and other underlying conditions, and it has been widely used in clinical practice. It is approved for the treatment of adults with iron deficiency with or without anemia, independent of the underlying condition, and is commercially available in Europe and the United States. We review the published evidence for ferric maltol, which demonstrates consistent and clinically meaningful improvements in hemoglobin and measures of iron availability (ferritin and transferrin saturation) and shows that it is well-tolerated over long-term treatment for up to 64 weeks—an important consideration in patients with chronic underlying conditions such as IBD and CKD. We believe that ferric maltol is an effective, convenient, and well-tolerated treatment option for iron deficiency and iron-deficiency anemia, especially when long-term management of chronic iron deficiency is required. Writing support was provided by Shield Therapeutics (Gateshead, UK).
format Online
Article
Text
id pubmed-8509126
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85091262021-10-13 Iron Replacement Therapy with Oral Ferric Maltol: Review of the Evidence and Expert Opinion Schmidt, Carsten Allen, Stephen Kopyt, Nelson Pergola, Pablo J Clin Med Review Iron deficiency is the most common cause of anemia globally and is frequently reported in patients with underlying inflammatory conditions, such as inflammatory bowel disease (IBD) and chronic kidney disease (CKD). Ferric maltol is a new oral iron replacement therapy designed to optimize iron absorption while reducing the gastrointestinal adverse events associated with unabsorbed free iron. Ferric maltol has been studied in clinical trials involving almost 750 adults and adolescents with iron-deficiency anemia associated with IBD, CKD, and other underlying conditions, and it has been widely used in clinical practice. It is approved for the treatment of adults with iron deficiency with or without anemia, independent of the underlying condition, and is commercially available in Europe and the United States. We review the published evidence for ferric maltol, which demonstrates consistent and clinically meaningful improvements in hemoglobin and measures of iron availability (ferritin and transferrin saturation) and shows that it is well-tolerated over long-term treatment for up to 64 weeks—an important consideration in patients with chronic underlying conditions such as IBD and CKD. We believe that ferric maltol is an effective, convenient, and well-tolerated treatment option for iron deficiency and iron-deficiency anemia, especially when long-term management of chronic iron deficiency is required. Writing support was provided by Shield Therapeutics (Gateshead, UK). MDPI 2021-09-28 /pmc/articles/PMC8509126/ /pubmed/34640466 http://dx.doi.org/10.3390/jcm10194448 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Schmidt, Carsten
Allen, Stephen
Kopyt, Nelson
Pergola, Pablo
Iron Replacement Therapy with Oral Ferric Maltol: Review of the Evidence and Expert Opinion
title Iron Replacement Therapy with Oral Ferric Maltol: Review of the Evidence and Expert Opinion
title_full Iron Replacement Therapy with Oral Ferric Maltol: Review of the Evidence and Expert Opinion
title_fullStr Iron Replacement Therapy with Oral Ferric Maltol: Review of the Evidence and Expert Opinion
title_full_unstemmed Iron Replacement Therapy with Oral Ferric Maltol: Review of the Evidence and Expert Opinion
title_short Iron Replacement Therapy with Oral Ferric Maltol: Review of the Evidence and Expert Opinion
title_sort iron replacement therapy with oral ferric maltol: review of the evidence and expert opinion
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509126/
https://www.ncbi.nlm.nih.gov/pubmed/34640466
http://dx.doi.org/10.3390/jcm10194448
work_keys_str_mv AT schmidtcarsten ironreplacementtherapywithoralferricmaltolreviewoftheevidenceandexpertopinion
AT allenstephen ironreplacementtherapywithoralferricmaltolreviewoftheevidenceandexpertopinion
AT kopytnelson ironreplacementtherapywithoralferricmaltolreviewoftheevidenceandexpertopinion
AT pergolapablo ironreplacementtherapywithoralferricmaltolreviewoftheevidenceandexpertopinion